Crude Oil Gains 3%; US Inflation Eases In April
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2025
0mins
Source: Benzinga
Stock Market Performance: U.S. stocks showed mixed results with the Dow Jones falling 0.49%, while the NASDAQ and S&P 500 gained 1.74% and 0.86%, respectively. Notable movements included a significant rise in information technology shares and declines in health care stocks.
Consumer Price Index Update: The annual inflation rate in the U.S. eased to 2.3% in April, slightly below expectations, indicating that new tariffs have not yet significantly impacted living costs.
Analyst Views on XENE
Wall Street analysts forecast XENE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XENE is 55.59 USD with a low forecast of 44.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
14 Buy
0 Hold
0 Sell
Strong Buy
Current: 40.740
Low
44.00
Averages
55.59
High
65.00
Current: 40.740
Low
44.00
Averages
55.59
High
65.00
About XENE
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
